-
Mashup Score: 0Case 2: Data Supporting Frontline TKI Therapy in Metastatic HCC - 2 year(s) ago
Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of sorafenib and lenvatinib, respectively.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Clinical Commentary: Addressing Challenges in Unresectable HCC and Adding Lenvatinib to Therapy Sequencing - 2 year(s) ago
During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, discussed therapeutic sequencing for patients with unresectable hepatocellular carcinoma and the use of lenvatinib versus sorafenib.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Treatment with tivozanib was associated with a fivefold increased likelihood of experiencing long-term progression-free survival compared to treatment with sorafenib.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 2Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial - 2 year(s) ago
First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib, but clinical activity and a favourable safety profile were observed in patients with advanced hepatocellular carcinoma. Thus, nivolumab might be considered a therapeutic option for patients in whom tyrosine kinase inhibitors and antiangiogenic drugs are contraindicated or have substantial risks.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial - 2 year(s) ago
First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib, but clinical activity and a favourable safety profile were observed in patients with advanced hepatocellular carcinoma. Thus, nivolumab might be considered a therapeutic option for patients in whom tyrosine kinase inhibitors and antiangiogenic drugs are contraindicated or have substantial risks.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Immune‐Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Recurrence of hepatocellular carcinoma (HCC) following liver transplantation (LT) occurs in 10%–20% of patients transplanted for HCC. The treatment of HCC recurrence after LT remains a challenge. Con…
Source: Wiley Online LibraryCategories: Latest Headlines, TransplantationTweet
-
Mashup Score: 1Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Sintilimab plus IBI305 showed a significant overall survival and progression-free survival benefit versus sorafenib in the first-line setting for Chinese patients with unresectable, HBV-associated hepatocellular carcinoma, with an acceptable safety profile. This combination regimen could provide a novel treatment option for such patients.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of #sorafenib and lenvatinib, #respectively. #HCC @MSKCancerCenter @NorthwesternMed @UTSWNews @HopkinsMedicine https://t.co/8ZoJrwYyXE